Ruiyun Xu

979 citations
36 papers · 745 indexed · h-index 15
Topics
Hepatocellular Carcinoma Treatment and Prognosis (12 papers)Liver physiology and pathology (10 papers)Liver Disease and Transplantation (7 papers)
Partner nations
ChinaUnited States

In The Last Decade

Ruiyun Xu

36 papers receiving 740 citations

Peers

Ruiyun Xu
Comparison fields: 5 of 71
  • Molecular Biology 334
  • Hepatology 260
  • Surgery 191
  • Cancer Research 187
  • Epidemiology 151
Replace Aihua Yao with:
Aihua Yao China
Takehiro Hayashi Japan
Ágnes Holczbauer United States
Di‐Peng Ou China
Verena Proell Austria
Giulia Orsi Italy
Marika Crescenzi Italy
Yefa Yang China
M Hisanaga Japan
Koichi Higaki Japan
Ruiyun Xu relative to Aihua Yao China Aihua Yao's profile →
Citations per field
00.5×2.8×
Aihua Yao · 1×
Citations per year

Countries citing papers authored by Ruiyun Xu

Since Specialization
Citations

This map shows the geographic impact of Ruiyun Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiyun Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiyun Xu more than expected).

Fields of papers citing papers by Ruiyun Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruiyun Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiyun Xu. The network helps show where Ruiyun Xu may publish in the future.

Co-authorship network of co-authors of Ruiyun Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruiyun Xu. A scholar is included among the top collaborators of Ruiyun Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiyun Xu. Ruiyun Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 7
2 11
3 13
4 17
5 97
6 34
7 14
8 49
9 13
10 36
11 10
12 2
13
Precautionary effect on the early application of anticoagulant drugs to portal vein thrombosis in patients with portal hypertension after operation.
1
14 53
15 10
16 24
17 50
18 8
19 4
20 28

About Ruiyun Xu

Ruiyun Xu is a scholar working on Hepatology, Cancer Research and Speech and Hearing, having authored 36 papers that have together received 745 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Liver physiology and pathology (10 papers) and Liver Disease and Transplantation (7 papers). The work is most often cited by research in Hepatology (260 citations), Cancer Research (187 citations) and Genetics (98 citations). Ruiyun Xu has collaborated with scholars based in China and United States. Frequent co-authors include Nan Lin, Mingxing Xu, Kunpeng Hu, Weidong Pan, Meihai Deng, Zhicheng Yao, Yi Lü, Yanjie Li, Si Chen and Yi Zhang. Their work appears in journals such as Biochemical and Biophysical Research Communications, Journal of Hepatology and Life Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026